Mitochondrial Marker Antibody Panel (Cytochrome C, COX4, HSP60) Reference: ARG30271 Mitochondrial Marker antibody; COX4 antibody; Hsp 60 antibody; Cytochrome C antibody
Nadunolimab Reference: HY-P99235 Nadunolimab is a human monoclonal IgG1 antibody targeting IL1RAP. Nadunolimab blocks IL-1α and IL-1β signaling and triggering antibody-dependent cellular cytotoxicity. Nadunolimab can be used in research of cancer.
Ruplizumab Reference: HY-P99315 Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research.
Efalizumab Reference: HY-P9947 Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.
Simlukafusp alfa Reference: HY-P99902 Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1.
Pro-apoptotic Bcl2 protein Antibody Panel (BAX, BAK, Bid) Reference: ARG30275 Pro-apoptotic Bcl2 protein antibody; Bax antibody; Bak antibody; Bid antibody
Abrezekimab Reference: HY-P99417 Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma.
Cytochrome-C fractionation Antibody Panel (Cytochrome-C, COX IV, beta Actin) Reference: ARG30276 Cytochrome-C fractionation antibody; beta Actin antibody; COX4 antibody; Cytochrome C antibody
Losatuxizumab Reference: HY-P99715 Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFRC271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.